AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36289459 — intervention group
Group type: EXPERIMENTAL
Intervention: High-score tercile of metabolites
Number of subjects: 190
Study 36291172 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigericin-stimulated whole blood samples from healthy donors
Number of subjects: 4
Study 36291172 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigericin-stimulated whole blood samples from septic shock patients
Number of subjects: 4
Study 36291397 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure time sport
Number of subjects: 505
Study 36291912 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMMAT-like metronomic antiangiogenic approach including daily oral thalidomide, fenofibrate, celecoxib, alternating 21-day cycles of low-dose oral etoposide and cyclophosphamide, IV bevacizumab, and intraventricular therapy with alternating etoposide and liposomal cytarabine.
Number of subjects: 29
Study 36293719 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic SARS-CoV-2 testing service (ATS)
Number of subjects: 25
Study 36294501 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 PCS ≤ 50
Number of subjects: 158
Study 36294501 — intervention group
Group type: EXPERIMENTAL
Intervention: mEHRA score
Number of subjects: 158
Study 36294501 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 MCS ≤ 50
Number of subjects: 158
Study 36294516 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive endovascular treatment for CVS
Number of subjects: 34
Study 36294516 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 34
Study 36295001 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP) transfusion (single unit with anti-RBD IgG concentration > 5 AU/mL)
Number of subjects: 189
Study 36295843 — intervention group
Group type: EXPERIMENTAL
Intervention: Untargeted SWATH metabolomics
Number of subjects: 886
Study 36295843 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration with pharmacogenomics data
Number of subjects: 886
Study 36296957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive Eating (IE) assessed using EPR and RHSC subscales
Number of subjects: 179
Study 36296957 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet quality assessed using the Alternative Health Eating Index (AHEI)
Number of subjects: 179
Study 36297443 — intervention group
Group type: EXPERIMENTAL
Intervention: DUO scheme (three cycles of [177Lu]Lu-DOTATOC alternated with two cycles of [90Y]Y-DOTATOC)
Number of subjects: 56
Study 36297443 — intervention group
Group type: EXPERIMENTAL
Intervention: MONO scheme (five cycles of [177Lu]Lu-DOTATOC)
Number of subjects: 56
Study 36297443 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DUO and MONO schemes
Number of subjects: 56
Study 36298700 — intervention group
Group type: EXPERIMENTAL
Intervention: cCMV infection
Number of subjects: 80
Study 36298700 — intervention group
Group type: EXPERIMENTAL
Intervention: EV-associated IP-10
Number of subjects: 80
Study 36298700 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of fetal infection
Number of subjects: 80
Study 36298700 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific increase in six proteins
Number of subjects: 80
Study 36298700 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal infection and its severity
Number of subjects: 80
Study 36299240 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-finger nuclease (ZFN) therapy at 1e13 vg/kg dose
Number of subjects: 13
Study 36299240 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-finger nuclease (ZFN) therapy at 5e13 vg/kg dose
Number of subjects: 13
Study 36299240 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-finger nuclease (ZFN) therapy for hemophilia B
Number of subjects: 13
Study 36299500 — intervention group
Group type: EXPERIMENTAL
Intervention: GAA enzyme assay
Number of subjects: 921
Study 36300324 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational, guided mHealth intervention to prevent postpartum mental health difficulties
Number of subjects: 0
Study 36300324 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36300352 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Recovery (answered yes to PASS at 1 and 6-months)
Number of subjects: 140
Study 36300352 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Recovery (PASS-yes only at 6-months)
Number of subjects: 140
Study 36300352 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrecovered
Number of subjects: 140
Study 36300352 — intervention group
Group type: COMPARATOR
Intervention: Early Recovery
Number of subjects: 140
Study 36300352 — intervention group
Group type: EXPERIMENTAL
Intervention: SPADI change scores
Number of subjects: 140
Study 36300352 — intervention group
Group type: EXPERIMENTAL
Intervention: QDASH change scores
Number of subjects: 140
Study 36300662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body negative pressure (LBNP) at -30 mmHg
Number of subjects: 1
Study 36300662 — intervention group
Group type: COMPARATOR
Intervention: Supine rest (baseline)
Number of subjects: 1
Study 36300662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body negative pressure (LBNP)
Number of subjects: 1
Study 36301137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (PD-1 inhibitor)
Number of subjects: 24
Study 36301338 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg
Number of subjects: 50
Study 36301338 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab 8 mg/kg
Number of subjects: 50
Study 36301572 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (200 mg twice daily)
Number of subjects: 24
Study 36301572 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib with radiotherapy
Number of subjects: 24
Study 36301599 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app with usual care
Number of subjects: 40
Study 36301599 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 40
Study 36301604 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training via a smartphone app (10 weekly sessions, daily practice)
Number of subjects: 0
Study 36301615 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based Cognition Kit Digit Symbol Substitution Test (DSST)
Number of subjects: 30
Study 36301615 — intervention group
Group type: COMPARATOR
Intervention: Standard paper-and-pencil version of the DSST
Number of subjects: 30
Study 36301921 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating biomarkers assessment (38 biomarkers: 27 proteins, 11 mRNAs) at sepsis diagnosis
Number of subjects: 203
Study 36301921 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical clustering and k-means algorithm for patient grouping
Number of subjects: 203
Study 36301928 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissolved tablet of EVG/COBI/FTC/TAF
Number of subjects: 12
Study 36301928 — intervention group
Group type: COMPARATOR
Intervention: Whole tablet of EVG/COBI/FTC/TAF
Number of subjects: 12
Study 36302159 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate insertion of contraceptive implants
Number of subjects: 2609
Study 36302159 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate insertion of IUDs
Number of subjects: 2609
Study 36302159 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion of contraceptive implants
Number of subjects: 2609
Study 36302159 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion of IUDs
Number of subjects: 2609
Study 36302159 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate insertion of progestin-releasing implants and IUDs
Number of subjects: 2609
Study 36302167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold atmospheric pressure plasma
Number of subjects: 0
Study 36302175 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine (subcutaneously, 45 mg/m2/day for 5 consecutive days, planned 28-day cycle)
Number of subjects: 9
Study 36302175 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Number of subjects: 9
Study 36302562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivuxolimab (0.1-3 mg/kg every 2 weeks) + utomilumab (20 or 100 mg every 4 weeks)
Number of subjects: 87
Study 36302562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivuxolimab (30 mg every 2 weeks) + utomilumab (20 mg every 4 weeks)
Number of subjects: 87
Study 36302579 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) in 2020
Number of subjects: 174
Study 36302579 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA during school hours in 2020
Number of subjects: 174
Study 36302579 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA during out-of-school time on weekdays in 2020
Number of subjects: 174
Study 36302579 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA during weekends in 2020
Number of subjects: 174
Study 36302579 — intervention group
Group type: COMPARATOR
Intervention: Participation in youth sports in 2020
Number of subjects: 174
Study 36302579 — intervention group
Group type: COMPARATOR
Intervention: Participation in youth clubs in 2020
Number of subjects: 174
Study 36302579 — intervention group
Group type: COMPARATOR
Intervention: Participation in other out-of-school activities in 2020
Number of subjects: 174
Study 36302579 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly physical education (PE) and recess minutes in 2020
Number of subjects: 174
Study 36302584 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 14543
Study 36302584 — intervention group
Group type: COMPARATOR
Intervention: Baseline eGFR <45 mL/min/1.73 m²
Number of subjects: 14543
Study 36302584 — intervention group
Group type: COMPARATOR
Intervention: Baseline eGFR 45-60 mL/min/1.73 m²
Number of subjects: 14543
Study 36302584 — intervention group
Group type: COMPARATOR
Intervention: Baseline eGFR >60 mL/min/1.73 m²
Number of subjects: 14543
Study 36302586 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-based prediction model (ABC-ACS ischemia score)
Number of subjects: 10713
Study 36302586 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth differentiation factor 15 and N-terminal pro-B-type natriuretic peptide biomarkers
Number of subjects: 10713
Study 36302586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression models
Number of subjects: 10713
Study 36303108 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation with continuous infusion of 8% trisodium citrate into the arterial line and supplementation of 1 M calcium chloride into the venous line
Number of subjects: 5
Study 36303108 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation
Number of subjects: 5
Study 36303136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented TKA
Number of subjects: 5961
Study 36303136 — intervention group
Group type: COMPARATOR
Intervention: Cementless TKA
Number of subjects: 5961
Study 36303332 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy program
Number of subjects: 16
Study 36303402 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular fibrillation (VF) group
Number of subjects: 14423
Study 36303402 — intervention group
Group type: COMPARATOR
Intervention: Non-VF group
Number of subjects: 14423
Study 36303432 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture-positive relapse
Number of subjects: 724
Study 36303432 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF WBC <5 cells/μL
Number of subjects: 724
Study 36303432 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 counts <50 cells/μL
Number of subjects: 724
Study 36303432 — intervention group
Group type: COMPARATOR
Intervention: First episodes of cryptococcal meningitis
Number of subjects: 724
Study 36303432 — intervention group
Group type: COMPARATOR
Intervention: Culture-positive relapses
Number of subjects: 724
Study 36303432 — intervention group
Group type: COMPARATOR
Intervention: Paradoxical IRIS
Number of subjects: 724
Study 36303445 — intervention group
Group type: EXPERIMENTAL
Intervention: eSCCIP (Electronic Surviving Cancer Competently Intervention Program)
Number of subjects: 44
Study 36303658 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely delivered, group-based lifestyle intervention
Number of subjects: 12
Study 36303659 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (CCVR)
Number of subjects: 130
Study 36303659 — intervention group
Group type: EXPERIMENTAL
Intervention: Net-En (injectable norethisterone-enanthate)
Number of subjects: 130
Study 36303659 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COC)
Number of subjects: 130
Study 36303659 — intervention group
Group type: COMPARATOR
Intervention: Control group (other contraceptive groups)
Number of subjects: 130
Study 36304034 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention by and for transgender women living with HIV
Number of subjects: 0
Study 36304034 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 36304240 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive measures (e.g., social distancing, mask usage)
Number of subjects: 4004
Study 36304457 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg every 3 weeks for ≤35 cycles
Number of subjects: 0
Study 36304457 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 36305298 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary mechanical circulatory supports and aggressive immunosuppression
Number of subjects: 0
Study 36305577 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and polysomnography (PSG)/multiple sleep latency test (MSLT) results
Number of subjects: 89
Study 36305577 — intervention group
Group type: COMPARATOR
Intervention: Comparison with European Narcolepsy Network (EU-NN) data
Number of subjects: 89
Study 36305957 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib 400 mg once-daily orally
Number of subjects: 1101
Study 36306154 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement-to-Music (M2M) program with behavioral telecoaching, 4-week duration, videos completed 3 times each week at home.
Number of subjects: 58
Study 36306154 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group maintaining daily activities.
Number of subjects: 58
Study 36306161 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE intervention (social media-based diabetes self-management videos delivered via WeChat, biweekly phone calls from community health workers)
Number of subjects: 60
Study 36306161 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 60
Study 36306158 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Intervention and Program of Support (TIPS) consisting of a 1-month training intervention with self-paced learning modules and a webinar, followed by an 11-month support program including monthly site meetings and access to a virtual community of practice.
Number of subjects: 20
Study 36306158 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS implementation assessed through an interrupted time series design.
Number of subjects: 20
Study 36306158 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data collection during implementation analyzed using a deductive-inductive thematic approach.
Number of subjects: 20
Study 36306158 — intervention group
Group type: EXPERIMENTAL
Intervention: Quasi-experimental pretest-posttest design using questionnaires.
Number of subjects: 20
Study 36306158 — intervention group
Group type: EXPERIMENTAL
Intervention: Manager, therapist, and family interviews conducted after implementation.
Number of subjects: 20
Study 36306158 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost data gathered to calculate public system and societal costs.
Number of subjects: 20
Study 36306162 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster emails containing personalized feedback
Number of subjects: 18
Study 36306162 — intervention group
Group type: COMPARATOR
Intervention: No booster emails (control group)
Number of subjects: 18
Study 36306335 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Bundle Branch Pacing (LBBP)
Number of subjects: 21
Study 36306335 — intervention group
Group type: COMPARATOR
Intervention: Biventricular Pacing (BVP)
Number of subjects: 21
Study 36306341 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated cardiac computed tomography (CT)
Number of subjects: 200
Study 36306341 — intervention group
Group type: COMPARATOR
Intervention: Lower fibrosis scores (1+2)
Number of subjects: 200
Study 36306387 — intervention group
Group type: EXPERIMENTAL
Intervention: In utero transfusions (IUTs)
Number of subjects: 60
Study 36306481 — intervention group
Group type: EXPERIMENTAL
Intervention: G8 Geriatric Screening Tool
Number of subjects: 1648
Study 36306481 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified G8 score
Number of subjects: 1648
Study 36306481 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Assessment (GA)
Number of subjects: 1648
Study 36306483 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Treatment Discontinuation (ETD)
Number of subjects: 10447
Study 36306483 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Oxaliplatin Discontinuation (EOD)
Number of subjects: 10447
Study 36306483 — intervention group
Group type: COMPARATOR
Intervention: 6 months of oxaliplatin-based chemotherapy
Number of subjects: 10447
Study 36306520 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP Difficulties Scale
Number of subjects: 0
Study 36306520 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP Confidence Scale
Number of subjects: 0
Study 36306532 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LADA
Number of subjects: 0
Study 36306532 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 0
Study 36306569 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor learning principles applied during physiotherapy sessions
Number of subjects: 57
Study 36306803 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 142
Study 36306810 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard whole-breast radiotherapy (40 Gy in 15 fractions or 50 Gy in 25 fractions) plus a boost (14 Gy in seven fractions) after image-guided VACB-determined pathological complete response following NST.
Number of subjects: 50
Study 36306921 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous tolerogenic dendritic cells (ATDC)
Number of subjects: 17
Study 36306921 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppression with basiliximab
Number of subjects: 17
Study 36307040 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg every 2 weeks)
Number of subjects: 1399
Study 36307044 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted next-generation sequencing covering 42 aortic diseases genes
Number of subjects: 73
Study 36307044 — intervention group
Group type: EXPERIMENTAL
Intervention: Family screening
Number of subjects: 73
Study 36307044 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis of demographic features, risk factors, and clinical symptoms
Number of subjects: 73
Study 36307158 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative exploration of character strengths among patients with breast cancer
Number of subjects: 24
Study 36307159 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported opioid consumption using a 14-day diary (paper or electronic)
Number of subjects: 166
Study 36307164 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative Care Referral System (PCRS) implemented after development and testing.
Number of subjects: 300
Study 36307164 — intervention group
Group type: COMPARATOR
Intervention: Standard care before implementation of PCRS.
Number of subjects: 300
Study 36307178 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk adenomas
Number of subjects: 15581
Study 36307178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk adenomas
Number of subjects: 15581
Study 36307178 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 15581
Study 36307178 — intervention group
Group type: EXPERIMENTAL
Intervention: Second colonoscopy
Number of subjects: 15581
Study 36307410 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad-sig-hMUC1/ecdCD40L adenoviral-vector vaccine
Number of subjects: 21
Study 36307462 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-β1b and lopinavir-ritonavir
Number of subjects: 70
Study 36307462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 36307601 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal lavage (PL) used in laparoscopic appendectomy (LA)
Number of subjects: 561
Study 36307601 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical evaluation of appendicitis severity
Number of subjects: 561
Study 36307601 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective difficulty assessment using a five-point Likert scale
Number of subjects: 561
Study 36307601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative findings of gangrenous or perforated appendicitis
Number of subjects: 561
Study 36307607 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser
Number of subjects: 100
Study 36307607 — intervention group
Group type: COMPARATOR
Intervention: Microkeratome
Number of subjects: 100
Study 36307738 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT combined with clinical parameters
Number of subjects: 0
Study 36307775 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT200 (anti-EGFR monoclonal antibody) administered intravenously every 3 weeks at doses ranging from 0.5-15.0 mg/kg.
Number of subjects: 56
Study 36307803 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with RKOA
Number of subjects: 282
Study 36307803 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with RKOA (normal BMI subgroup, n=126)
Number of subjects: 282
Study 36307803 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with obesity
Number of subjects: 282
Study 36307803 — intervention group
Group type: COMPARATOR
Intervention: Individuals without RKOA
Number of subjects: 282
Study 36307826 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin, administered for a median of 4.5 cycles (1-23 cycles), with a median overall survival of 12 months.
Number of subjects: 180
Study 36307826 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin, with reported severe AEs including neutropenia (15.3%) and neurotoxicity (14.7%).
Number of subjects: 180